The specification relates to compounds of Formula (1):
The specification relates to compounds of Formula (1):
The specification relates to compounds of Formula (1):
and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of diseases such as liver disease.
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present disclosure relates to methods and dosage regimen for treating or preventing a FAP-mediated condition, comprising administering to the subject a compound of Formula (I), as defined herein, or a pharmaceutically acceptable salt thereof.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present disclosure provides compounds represented by Formula (I), or a pharmaceutically acceptable salt and/or stereoisomer thereof: wherein Ra, Rb, Rc, R7, R8, R9, R10, X3, W, L, and E are as defined in the specification. Compounds represented by Formula (I) are SMARCA2 protein degraders and are thus useful for treating cancer and other diseases.
The present invention provides a pharmaceutical tablet formulation of tenapanor that is chemically stable and soluble comprising greater than about 6% w/w of amorphous tenapanor in its bis-HCl form, an acidifying agent, an antioxidant, a disintegrant, a lubricant, a glidant, a filler, and an immediate release coating, wherein the total chloride content of the active ingredient is greater than 5.82% and the particle diameter distribution D50 is from about from about 18 μm to about 22 μm.
The specification relates to conjugates comprising one or more DM and pharmaceutically acceptable salts thereof. The specification also relates the use of the conjugates for the treatment of diseases such as cancer, and intermediates useful for the synthesis of the conjugates.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure relates to dosage regimens for the administration of a recombinant apyrase protein and their medical use in the treatment of ischemic events in a patient, such as ST-segment elevation myocardial infarction and acute ischemic stroke.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
12.
CLAUDIN 18.2 ANTIBODIES, ANTIGEN BINDING FRAGMENTS AND ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE IN CANCER THERAPY
Provided are antibodies, antigen binding fragments, and immunoconjugates thereof that specifically bind to claudin 18.2 expressing cells, along with pharmaceutical compositions and kits comprising the antibodies, antigen binding fragments, and/or immunoconjugates. Methods of use of the antibodies, antigen binding fragments, and immunoconjugates in the treatment of claudin 18.2 expressing tumor cells is also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
21.
SYSTEMS AND METHODS FOR END TO END CONTINUOUS DOWNSTREAM PROCESSING
Provided herein are methods of purifying proteins of interest using continuous counter-current downstream processing. Also provided herein are methods of purifying proteins of interest using continuous counter-current affinity nanoparticle dialysis.
The present disclosure relates to methods of treating PTEN-deficient metastatic hormone- sensitive prostate cancer (mHSPC) in patients in need thereof, the methods comprising administering to the patients a combination comprising capivasertib or a pharmaceutically acceptable salt thereof; and abiraterone or an ester prodrug thereof, or a pharmaceutically acceptable salt thereof.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
25.
COMPOSITIONS AND METHODS FOR DELIVERING A MACROMOLECULE TO A CELL
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Disclosed herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, Y1, X2, Y2, a, b, c, d, e and f are as defined herein. Also disclosed are lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a plurality of lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a nucleic acid segment; as well as methods for delivering a nucleic acid segment comprising administering a plurality of lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a nucleic acid segment.
Disclosed herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, Y1, X2, Y2, a, b, c, d, e and f are as defined herein. Also disclosed are lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a plurality of lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a nucleic acid segment; as well as methods for delivering a nucleic acid segment comprising administering a plurality of lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a nucleic acid segment.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
The present disclosure relates to an mRNA molecule encoding a polypeptide comprising an hMPV F protein, or an immunogenic fragment thereof, and a lumazine synthase (LuS) capable of multimerising to form a nanoparticle. Further aspects of the disclosure relate to compositions comprising the mRNA molecule and their use as a vaccine in the prevention of infectious diseases, including those caused by hMPV and RSV.
The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of cancer, wherein the EGFR TKI is administered in combination with an inhibitor of c-MET.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Antibodies for medical purposes; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Antibodies for medical purposes; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines
31.
COMPOUNDS AND METHODS FOR REDUCING ARHGEF6 EXPRESSION
Provided are oligonucleotides, polynucleotide conjugates, and compositions and populations comprising the same, as well as methods and uses thereof for reducing the amount or activity of Rho guanine nucleotide exchange factor 6 (ARHGEF6) RNA in a cell or animal, and in certain instances reducing the amount of ARHGEF6 protein in a cell or animal Such oligonucleotides, polynucleotide conjugates, and compositions and populations, methods and uses are useful to treat kidney diseases or conditions. In particular, such oligonucleotides, polynucleotide conjugates, and compositions and populations, methods and uses are useful to treat chronic kidney disease, such as diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), renal hypertension (HTN), IgA nephropathy / Berger's disease (IgAN), rapidly progressive glomerulonephritis (RPGN) and systemic lupus erythematosus (SLE).
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The disclosure relates to methods and compositions for the treatment of systemic lupous erythematosus (SLE). Specifically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
The specification relates to the administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists for the treatment in a subject in need thereof.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
The specification relates to the administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The specification relates to the administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists for the for chronic weight management and the treatment of obesity and overweight.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The specification relates to the co- administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists and SGLT-2 inhibitors.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
The specification relates to the co- administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists and PCSK9 inhibitors.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
The specification relates to the administration of small molecule, once-daily, oral glucagon-like peptide-1 receptor agonists for the treatment of inflammatory disorders and autoimmune disorders.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
Provided are compositions of a multi-specific T-cell engager comprising a claudin 18.2 (CLDN18.2) binding site and a T cell binding site, in combination with a checkpoint inhibitor agent and/or one or more chemotherapy agent(s), and methods of use therefor. Methods for treating a patient having a CLDN18.2-expressing solid tumor with a bispecific T cell engager (BsTCE), comprising a first domain that binds to CLDN18.2 and a second domain that binds to a T cell, in combination with a checkpoint inhibitor agent and/or one or more chemotherapy agent(s) are disclosed. Also provided are pharmaceutical compositions comprising provided combinations, such pharmaceutical composition combinations for use in the treatment of a CLDN18.2-expressing cancer, and the use of such pharmaceutical composition combinations for the manufacture of a medicament for treating a CLDN18.2-expressing cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present disclosure provides modulators or inhibitors of Artemis and their uses for promoting sequence integration into a target genomic locus in a cell by non-homologous end joining-mediated prime editing.
Methods for treating chronic kidney disease and liver fibrosis in patients using a fixed-dose combination of zibotentan and dapagliflozin are disclosed.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The specification relates to conjugates comprising a linker of Formula (IA) and pharmaceutically acceptable salts thereof. The specification also relates the use of the conjugates for the treatment of diseases such as cancer, and intermediates useful for the synthesis of the conjugates.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The specification relates to conjugates of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates the use of the conjugates for the treatment of diseases such as cancer, and intermediates useful for the synthesis of the conjugates.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Methods for treating chronic kidney disease and liver fibrosis in patients using a fixed-dose combination of zibotentan and dapagliflozin are disclosed.
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
There are disclosed certain double-stranded RNA (dsRNA) or siRNA agents for inhibition of angiopoietin-like 3 gene expression, compositions that include angiopoietin-like 3 agents and methods of use thereof. The double-stranded RNA (dsRNA) or siRNA agents are particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions as well as in the treatment of heart failure and chronic kidney disease.
The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine.
The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Antibodies for medical purposes; Vaccines
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
74.
LIQUID-PHASE OLIGONUCLEOTIDE SYNTHESIS USING 2-(2-NITROPHENYL)PROPYLOXYCARBONYL (NPPOC) AS A PROTECTING GROUP
A process of liquid-phase oligonucleotide synthesis (LPOS) is provided which uses the photolabile protecting group 2-(2-nitrophenyl)propyloxycarbonyl (NPPOC). The process may be used for synthesizing an NPPOC-protected oligonucleotide or salt thereof or a precursor thereto. Also provided is the use of NPPOC in liquid phase oligonucleotide synthesis, as well as an NPPOC-protected oligonucleotide or salt thereof which is in solution.
C07H 1/00 - Processes for the preparation of sugar derivatives
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Pharmaceutical preparations for use in oncology; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Pharmaceutical preparations for use in oncology; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Pharmaceutical preparations for use in oncology; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Pharmaceutical preparations for use in oncology; Vaccines; Antibodies for medical purposes
79.
TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES
A method of treating cancer in a subject in need thereof is provided herein, the method comprising administering to the subject an antibody-drug conjugate (ADC) in an amount from about 0.8 mg/kg to about 5.0 mg/kg, wherein the ADC comprises an anti-FRα antibody or antigen-binding fragment thereof linked to a cytotoxin, wherein the cytotoxin is a topoisomerase I inhibitor.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Disclosed are methods for treating solid tumors with an anti-PD-L1 antibody and an anti-CTLA-4 antibody concurrently with chemoradiation therapy (cCRT).
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
Therapeutic combinations of an AKT inhibitor and a BCL-2 inhibitor; an AKT inhibitor and a glucocorticoid; and an AKT inhibitor, a BCL-2 inhibitor and a glucocorticoid are described. The combinations can be useful in the treatment of acute lymphoblastic leukemia (ALL).
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61P 35/02 - Antineoplastic agents specific for leukemia
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, dermatological, neurological, gastrointestinal, and immune systems; Pharmaceutical preparations for the treatment of infection, inflammation, hematological, and autoimmune related diseases and disorders; Vaccines; Antibodies for medical purposes
Compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5, and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
Compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5, and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
91.
RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION
The specification generally relates to uses of to uses of RXFP1 modulators, in particular methods of treating resistant hypertension and heart failure with pulmonary hypertension.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
The specification generally relates to combinations of RXFP1 modulators and SGLT2 inhibitors, in particular pharmaceutical compositions comprising such combinations, and therapeutic methods using such combinations.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
The present disclosure relates to a recombinant poxvirus comprising in its genome a heterologous nucleic acid sequence encoding interleukin-12 (IL-12). Methods for producing the recombinant poxvirus, compositions (e.g., pharmaceutical compositions) comprising the recombinant poxvirus, methods of treating cancer using the recombinant poxvirus, and kits comprising the recombinant poxvirus are provided.
Described herein is an auto-injector for receiving and operating a cassette, which includes a medicinal container, needle, and needle cover. The auto-injector features a main body and a lever that can move between open and closed positions. In the open position, the cassette can be inserted or removed. The auto-injector also has a latch system holding a plunger rod in a retracted position to accommodate the cassette. A linkage system, coupled to the plunger rod, releases the plunger rod when pressed against the skin, using energy from a main drive spring to deliver the medication via the needle of the cassette. After delivery, opening the lever slides the plunger rod distally to recharge the spring.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
